New York State Common Retirement Fund’s Protalix BioTherapeutics PLX Stock Holding History

New York State Common Retirement Fund’s Portfolio PLX Stock Details PLX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$72.5K	Hold	31,100	–	–	﹤0.01%	2848
2026 Q1	$67.5K	Hold	31,100	–	–	﹤0.01%	2710
2025 Q4	$56K	Sell	31,100 -10,200	-25%	-$20.9K	﹤0.01%	2875
2025 Q3	$91.7K	Sell	41,300 -27,700	-40%	-$45.1K	﹤0.01%	2664
2025 Q2	$102K	Buy	+69,000	New	+$141K	﹤0.01%	2621
2024 Q3	–	Sell	-555	Closed	-$649	–	3305
2024 Q2	$649	Sell	555 -45,100	-99%	-$53.3K	﹤0.01%	3316
2024 Q1	$57.5K	Buy	45,655 +555	+1%	+$829	﹤0.01%	2943
2023 Q4	$80.3K	Sell	45,100 -700	-2%	-$1.09K	﹤0.01%	2830
2023 Q3	$76K	Buy	45,800 +700	+2%	+$1.26K	﹤0.01%	2855
2023 Q2	$90.2K	Buy	+45,100	New	+$107K	﹤0.01%	2944

Other funds holding PLX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

SWP

Stratos Wealth Partners Beachwood, Ohio $9.93B AUM 28.91% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

New York State Common Retirement Fund's PLX Position: Q2 2026 in Review

New York State Common Retirement Fund held its Protalix BioTherapeutics (PLX) position steady in Q2 2026 at 31,100 shares worth $72.5K. The position accounts for ﹤0.01% of the portfolio, ranked #2848.

New York State Common Retirement Fund first reported a position in PLX in Q2 2023 and has held it in 10 quarters since. The position peaked at $102K in Q2 2025. 101 funds tracked by Wall St. Rank hold PLX as of Q2 2026.

New York State Common Retirement Fund held 31,100 shares of Protalix BioTherapeutics worth $72.5K as of Q2 2026.
New York State Common Retirement Fund left its Protalix BioTherapeutics share count unchanged in Q2 2026.
Protalix BioTherapeutics made up ﹤0.01% of New York State Common Retirement Fund's portfolio in Q2 2026, its #2848 holding.
New York State Common Retirement Fund first reported a position in Protalix BioTherapeutics in Q2 2023 and has held it in 10 quarters since.
New York State Common Retirement Fund's Protalix BioTherapeutics position peaked at $102K in Q2 2025.
101 funds tracked by Wall St. Rank held Protalix BioTherapeutics as of Q2 2026.

Based on New York State Common Retirement Fund's 13F filing for Q2 2026, filed 29 Jul 2026.